|Other Names||Tektin-1, TEKT1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3563a was selected from the region of human Phospho-TEK-pY1113. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Structural component of ciliary and flagellar microtubules. Forms filamentous polymers in the walls of ciliary and flagellar microtubules.|
|Cellular Location||Cytoplasm, cytoskeleton, cilium axoneme. Cytoplasm, cytoskeleton, flagellum axoneme|
|Tissue Location||Predominantly expressed in testis.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The TEK receptor tyrosine kinase is expressed almost exclusively in endothelial cells in mice, rats, and humans. This receptor possesses a unique extracellular domain containing 2 immunoglobulin-like loops separated by 3 epidermal growth factor-like repeats that are connected to 3 fibronectin type III-like repeats. The ligand for the receptor is angiopoietin-1. Defects in TEK are associated with inherited venous malformations; the TEK signaling pathway appears to be critical for endothelial cell-smooth muscle cell communication in venous morphogenesis. TEK is closely related to the TIE receptor tyrosine kinase.
Cascone, I., et al., Blood 102(7):2482-2490 (2003).DeBusk, L.M., et al., Arthritis Rheum. 48(9):2461-2471 (2003).Poncet, S., et al., Neuropathol Appl Neurobiol 29(4):361-369 (2003).Lee, H.J., et al., Biochem. Biophys. Res. Commun. 304(2):399-404 (2003).Sussman, L.K., et al., Cancer Biol. Ther. 2(3):255-256 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.